Show simple item record

dc.contributor.authorSchifano, Fabrizio
dc.contributor.authorPapanti, Duccio
dc.contributor.authorOrsolini, Laura
dc.contributor.authorCorkery, John
dc.date.accessioned2017-06-22T16:34:19Z
dc.date.available2017-06-22T16:34:19Z
dc.date.issued2016-07-02
dc.identifier.citationSchifano , F , Papanti , D , Orsolini , L & Corkery , J 2016 , ' Novel Psychoactive Substances: the pharmacology of stimulants and hallucinogens ' , Expert Review of Clinical Pharmacology , vol. 9 , no. 7 , pp. 943-54 . https://doi.org/10.1586/17512433.2016.1167597
dc.identifier.issn1751-2441
dc.identifier.otherPURE: 10023008
dc.identifier.otherPURE UUID: 1903ac8e-2174-4e5d-b55e-c738c5633310
dc.identifier.otherScopus: 84962124713
dc.identifier.urihttp://hdl.handle.net/2299/18468
dc.descriptionThis is an Accepted Manuscript of an article published by Taylor & Francis in Expert Review of Clinical Pharmacology, on March 2016, available online at doi: : http://www.tandfonline.com/doi/full/10.1586/17512433.2016.1167597.
dc.description.abstractThere are increasing levels of concern relating to the rapidly evolving novel psychoactive substances/NPS and web markets’ scenarios. The paper aims at providing an overview of the clinical pharmacological issues related to some of the most popular NPS categories, e.g. stimulants and hallucinogens. NPS intake is typically associated with the imbalance of a complex range of neurotransmitter pathways/receptors, namely: dopamine; cannabinoid/CB1; and 5-HT2A. The intake is almost invariably undetectable with standard screening tests. Hence, it may frequently occur that the acute management of NPS misusers will need to focus on decreasing levels of both self/outward-directed aggression and agitation. Benzodiazepines may be considered as first line treatment. Alternatively, propofol and/or antipsychotics can be administered. Focus will be as well on treatment of possible rhabdomyolysis and hyperthermia. Indeed, future studies should inform better tailored management/treatment strategies.en
dc.format.extent12
dc.language.isoeng
dc.relation.ispartofExpert Review of Clinical Pharmacology
dc.subjectNovel Psychoactive Substances
dc.subjectSynthetic cannabimimetics
dc.subjectSynthetic cathinones
dc.subjectHallucinogenic drugs
dc.subjectPhenethylamines
dc.subjectPsychiatric disturbances
dc.subjectDrug misuse
dc.titleNovel Psychoactive Substances: : the pharmacology of stimulants and hallucinogensen
dc.contributor.institutionSchool of Life and Medical Sciences
dc.contributor.institutionCentre for Clinical Practice, Safe Medicines and Drug Misuse Research
dc.contributor.institutionPatient and Medicines Safety
dc.contributor.institutionPrescription and Illicit Drug Misuse
dc.contributor.institutionDepartment of Pharmacy, Pharmacology and Postgraduate Medicine
dc.contributor.institutionPublic Health
dc.contributor.institutionPsychopharmacology, Drug Misuse and Novel Psychoactive Substances Unit
dc.contributor.institutionCentre for Health Services and Clinical Research
dc.description.statusPeer reviewed
dc.date.embargoedUntil2017-04-04
dc.identifier.urlhttps://www.researchgate.net/profile/Laura_Orsolini/publication/298788436_Novel_Psychoactive_Substances_the_pharmacology_of_stimulants_and_hallucinogens/links/5712a6a108ae4ef745261948.pdf
rioxxterms.versionAM
rioxxterms.versionofrecordhttps://doi.org/10.1586/17512433.2016.1167597
rioxxterms.typeJournal Article/Review
herts.preservation.rarelyaccessedtrue


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record